Production of non-GMP batches of paynantheine, speciogynine, and speciociliatine salts
Ended Awarded Last action
- Contract number
- 75N95020F00001
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,174,494
Award facts
- Opportunity
-
- 75N95020R00041 Solicitation number
- Contract value 93% obligated
-
- $1,174,494.49 Current, with exercised options
- $1,259,570.66 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,174,494 |
About this award
This federal contract award to Curia Global Inc., doing business as Amri, is for the production of non-GMP (non-Good Manufacturing Practice) batches of the drug substances paynantheine, speciogynine, and speciociliatine salts. The contract, valued at $1,259,570.66, was awarded under the National Institute on Drug Abuse's (NIDA) indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for Contract Research Organization (CRO) Support for NCATS Drug Substance Development and Manufacture. This award does not have a set-aside designation. Curia Global Inc. is a leading global contract development and manufacturing organization (CDMO) with extensive experience supporting various National Institutes of Health (NIH) institutes and other federal agencies through prime and subcontract awards, focusing on therapeutic development initiatives in areas such as neurology, infectious diseases, and substance abuse.
Quick answers
Who was awarded contract 75N95020F00001?
75N95020F00001 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 16, 2020.
How much is contract 75N95020F00001 worth?
The government has obligated $1,174,494 on 75N95020F00001. Its potential value, with all options, is $1,259,571.
Is contract 75N95020F00001 an order under another contract?
Yes. 75N95020F00001 is a delivery order under HHSN271201700005I, an indefinite delivery contract, on CRO Support for NCATS Drug Substance Development and Manufacture.
Was contract 75N95020F00001 competed?
The extent of competition for 75N95020F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award